⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for palbociclib

Every month we try and update this database with for palbociclib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.NCT06086340
Breast Cancer
Palbociclib
Aromatase Inhib...
65 Years - Pfizer
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)NCT04964934
ER-Positive HER...
AZD9833
AZD9833 Placebo
Anastrozole
Anastrozole pla...
Letrozole
Letrozole place...
Palbociclib
Abemaciclib
Luteinizing hor...
Ribociclib
18 Years - 130 YearsAstraZeneca
Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian CancerNCT03936270
Ovarian Cancer
Palbociclib 125...
Letrozole 2.5mg
18 Years - Latin American Cooperative Oncology Group
PALBOCICLIB + PD-0325901 for NSCLC & Solid TumorsNCT02022982
KRAS Mutant Non...
Solid Tumors
Palbociclib
PD-0325901
18 Years - Dana-Farber Cancer Institute
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseaseNCT04711252
ER-Positive HER...
AZD9833
Anastrozole
Anastrozole pla...
AZD9833 placebo
Palbociclib
Luteinizing hor...
18 Years - 130 YearsAstraZeneca
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)NCT03297606
Lymphoma, Non-H...
Multiple Myelom...
Advanced Solid ...
Olaparib
Dasatinib
Nivolumab plus ...
Axitinib
Bosutinib
Crizotinib
Palbociclib
Sunitinib
Temsirolimus
Erlotinib
Trastuzumab plu...
Vemurafenib plu...
Vismodegib
Tucatinib
18 Years - Canadian Cancer Trials Group
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.NCT04852081
Breast Cancer S...
Palbociclib
Ribociclib
Abemaciclib
Letrozole
Anastrozole
Tamoxifen
Fulvestrant
Exemestane
Alpelisib
18 Years - Blokhin's Russian Cancer Research Center
Observational Analysis of Palbociclib Treatment in Patients With First Line Therapy for Locally Advanced and/or Metastatic Breast CancerNCT04874025
Breast Cancer
Ibrance
18 Years - Hospital San Carlos, Madrid
Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBCNCT03184090
Metastatic Brea...
Palbociclib
Endocrine thera...
18 Years - MedSIR
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid TumorsNCT03454035
Tumor, Solid
Pancreatic Canc...
Melanoma
Ulixertinib
Palbociclib
18 Years - 99 YearsUNC Lineberger Comprehensive Cancer Center
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast CancerNCT03685331
Metastatic Brea...
Locally Advance...
Advanced Breast...
BRCA2 Mutation
BRCA1 Mutation
Palbociclib
Olaparib
Fulvestrant
18 Years - Abramson Cancer Center at Penn Medicine
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)NCT01942135
Metastatic Brea...
Palbociclib
Fulvestrant
Placebo
Fulvestrant
18 Years - Pfizer
Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant ChemotherapyNCT04137640
Breast Cancer
palbociclib com...
epirubicin comb...
18 Years - 70 YearsShengjing Hospital
Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ETNCT04992156
Metastatic Brea...
Palbociclib
18 Years - 70 YearsFudan University
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)NCT03526250
Advanced Malign...
Recurrent Child...
Recurrent Ewing...
Recurrent Gliom...
Recurrent Hepat...
Recurrent Kidne...
Recurrent Lange...
Recurrent Malig...
Recurrent Malig...
Recurrent Medul...
Recurrent Neuro...
Recurrent Non-H...
Recurrent Osteo...
Recurrent Perip...
Recurrent Rhabd...
Recurrent Rhabd...
Recurrent Soft ...
Refractory Epen...
Refractory Ewin...
Refractory Glio...
Refractory Hepa...
Refractory Lang...
Refractory Mali...
Refractory Mali...
Refractory Medu...
Refractory Neur...
Refractory Non-...
Refractory Oste...
Refractory Peri...
Refractory Rhab...
Refractory Rhab...
Refractory Soft...
Laboratory Biom...
Palbociclib
Pharmacological...
12 Months - 21 YearsNational Cancer Institute (NCI)
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast CancerNCT04191499
Breast Cancer
Inavolisib
Placebo
Palbociclib
Fulvestrant
18 Years - Hoffmann-La Roche
A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast CancerNCT05584644
Breast Cancer
Breast Carcinom...
Breast Neoplasm...
Breast Tumors
Cancer of Breas...
Palbociclib plu...
Palbociclib plu...
18 Years - 99 YearsPfizer
Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase InhibitorsNCT02028507
Metastatic Brea...
Palbociclib
Capecitabine
Exemestane
Fulvestrant
18 Years - Spanish Breast Cancer Research Group
Palbociclib With Cisplatin or Carboplatin in Advanced Solid TumorsNCT02897375
Solid Neoplasm
Stage III Pancr...
Stage IIIA Brea...
Stage IIIA Non-...
Stage IIIB Brea...
Stage IIIB Non-...
Stage IIIC Brea...
Stage IV Breast...
Stage IV Non-Sm...
Stage IVA Pancr...
Stage IVB Pancr...
Sarcoma
Colorectal Canc...
Head and Neck C...
Cancer of Unkno...
Bladder Cancer
Ovarian Cancer
Carboplatin
Cisplatin
Palbociclib
18 Years - Emory University
Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast CancerNCT02690480
Breast Neoplasm...
PD-0332991 (Pal...
Fulvestrant
Placebo
18 Years - Spanish Breast Cancer Research Group
A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast CancerNCT02296801
Breast Cancer
Breast Carcinom...
Breast Tumors
Letrozole
palbociclib
18 Years - NSABP Foundation Inc
Palbociclib and Pembrolizumab in Undifferentiated Pleomorphic Sarcoma (UPS)NCT06113809
Undifferentiate...
Palbociclib
Pembrolizumab
12 Years - University of Iowa
PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studYNCT03423199
Breast Neoplasm...
Palbociclib
Placebo
Tamoxifen
Goserelin
18 Years - National Cancer Center, Japan
Study of PF-07248144 in Advanced or Metastatic Solid TumorsNCT04606446
Locally Advance...
Locally Advance...
Locally Advance...
PF-07248144
Fulvestrant
Letrozole
Palbociclib
PF-07220060
18 Years - Pfizer
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsNCT06188520
ER+ HER2- Advan...
High-grade Sero...
AZD8421
Camizestrant
Ribociclib
Palbociclib
Abemaciclib
18 Years - AstraZeneca
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast CancerNCT02947685
HER-2 Positive ...
Estrogen Recept...
palbociclib
trastuzumab
pertuzumab
letrozole
Anastrozole
Exemestane
Fulvestrant
18 Years - Alliance Foundation Trials, LLC.
To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine TherapyNCT02549430
Breast Cancer
Palbociclib
Anastrozole
Letrozole
Exemestane
Fulvestrant
18 Years - Fondazione Sandro Pitigliani
Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB PreservedNCT02530320
Oligodendroglio...
Oligoastrocytom...
Palbociclib
18 Years - Grupo Español de Investigación en Neurooncología
Patterns of Treatment and Outcome of Palbociclib Plus Endocrine TherapyNCT04524728
Breast
Neoplasm Malign...
Female
Palbociclib
Letrozole 2.5mg
Fulvestrant
18 Years - Istituti Clinici Scientifici Maugeri SpA
Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)NCT03065621
Breast Cancer F...
Palbociclib
18 Years - Jules Bordet Institute
A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast CancerNCT05909397
Breast Cancer
ARV-471 (PF-078...
Palbociclib
Letrozole
Palbociclib
18 Years - Pfizer
A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).NCT03355157
Metastatic Brea...
Palbociclib / C...
18 Years - German Breast Group
Palbociclib In Progressive Brain MetastasesNCT02896335
Metastatic Mali...
Palbociclib
18 Years - Massachusetts General Hospital
A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.NCT04671615
Metastatic Brea...
palbociclib
18 Years - 99 YearsPfizer
Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine TherapyNCT03220178
Breast Neoplasm
Palbociclib
Fulvestrant
Anastrozole
Letrozole
Exemestane
18 Years - Palleos Healthcare GmbH
Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine MonotherapyNCT04736576
Breast Cancer
Wearable device
20 Years - Pfizer
Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast CancerNCT03900884
Breast Neoplasm...
Venetoclax
Palbociclib
Letrozole
18 Years - Peter MacCallum Cancer Centre, Australia
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)NCT04185883
Advanced Solid ...
Kirsten Rat Sar...
Sotorasib
Trametinib
RMC-4630
Afatinib
Pembrolizumab
Panitumumab
Carboplatin, pe...
Atezolizumab
Palbociclib
MVASI® (bevaciz...
TNO155
IV Chemotherapy...
IV Chemotherapy...
BI 1701963
AMG 404
Everolimus
18 Years - 100 YearsAmgen
Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in ChinaNCT04526028
Breast Cancer
Fulvestrant
Palbociclib
Fulvestrant Inj...
Palbociclib
18 Years - Tianjin Medical University Cancer Institute and Hospital
Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATENCT04720768
Melanoma
Metastasis
Binimetinib
Encorafenib
Palbociclib
18 Years - 100 YearsPeter MacCallum Cancer Centre, Australia
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerNCT03709082
HER2-positive B...
Breast Cancer M...
Palbociclib 75m...
Letrozole 2.5mg
T-DM1
Palbociclib 100...
Palbociclib 125...
Palbociclib
18 Years - University of Kansas Medical Center
Palbociclib With Cisplatin or Carboplatin in Advanced Solid TumorsNCT02897375
Solid Neoplasm
Stage III Pancr...
Stage IIIA Brea...
Stage IIIA Non-...
Stage IIIB Brea...
Stage IIIB Non-...
Stage IIIC Brea...
Stage IV Breast...
Stage IV Non-Sm...
Stage IVA Pancr...
Stage IVB Pancr...
Sarcoma
Colorectal Canc...
Head and Neck C...
Cancer of Unkno...
Bladder Cancer
Ovarian Cancer
Carboplatin
Cisplatin
Palbociclib
18 Years - Emory University
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)NCT05468697
Renal Cell Carc...
Belzutifan
Palbociclib
18 Years - Merck Sharp & Dohme LLC
Analysis of Palbociclib Treatment in Patients With Advanced Breast Cancer Within a Compassionate Use ProgrameNCT04109261
Breast Cancer
Palbociclib
18 Years - 100 YearsHospital San Carlos, Madrid
A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial TumorNCT03219554
Thymic Cancer
Palbociclib
18 Years - Samsung Medical Center
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02785939
CCND1 Gene Ampl...
CCND2 Gene Ampl...
CCND3 Gene Ampl...
CDK4 Gene Ampli...
Recurrent Squam...
Stage IV Squamo...
Docetaxel
Laboratory Biom...
Palbociclib
18 Years - SWOG Cancer Research Network
Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor AloneNCT05012644
Metastatic Brea...
Palbociclib + a...
Aromatase inhib...
- Pfizer
Biomarker-based Study in R/M SCCHNNCT03088059
Carcinoma, Squa...
Afatinib
Palbociclib
standard of car...
IPH2201
Durvalumab
Niraparib
INCAGN01876
18 Years - European Organisation for Research and Treatment of Cancer - EORTC
Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal TherapyNCT04318223
Metastatic Brea...
Locally Advance...
Palbociclib
18 Years - 64 YearsConsorzio Oncotech
Study of Palbociclib in MLL-rearranged Acute LeukemiasNCT02310243
Acute Myeloid L...
Acute Lymphobla...
Palbociclib
18 Years - University of Ulm
A Study of ZN-c5 in Subjects With Breast CancerNCT03560531
Breast Cancer
ZN-c5
Palbociclib
18 Years - Zeno Alpha Inc.
A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBCNCT02592746
Metastatic Brea...
Palbociclib
Exemestane
Leuprolide Acet...
Capecitabine
19 Years - Samsung Medical Center
Study of PF-07248144 in Advanced or Metastatic Solid TumorsNCT04606446
Locally Advance...
Locally Advance...
Locally Advance...
PF-07248144
Fulvestrant
Letrozole
Palbociclib
PF-07220060
18 Years - Pfizer
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast CancerNCT03774472
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Hydroxychloroqu...
Letrozole
Palbociclib
18 Years - M.D. Anderson Cancer Center
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerNCT02664935
Non-Small Cell ...
Carcinoma, Squa...
Adenocarcinoma
AZD4547
Vistusertib
Palbociclib
Crizotinib
Selumetinib
Docetaxel
AZD5363
Osimertinib
Durvalumab
Sitravatinib
AZD6738
18 Years - University of Birmingham
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)NCT03792256
Leukemia, Lymph...
Lymphoblastic L...
T-cell Lymphoma
T-cell Leukemia
Recurrent Disea...
Acute Leukemia
Palbociclib
Cytarabine
Methotrexate
Hydrocortisone
Doxorubicin
Prednisolone
Vincristine
Pegaspargase
Hydrocortisone
Prednisone
12 Months - 31 YearsChildren's Oncology Group
A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast CancerNCT04075604
Breast Cancer
Cancer
Nivolumab
Anastrozole
Palbociclib
18 Years - Bristol-Myers Squibb
Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian CancerNCT03936270
Ovarian Cancer
Palbociclib 125...
Letrozole 2.5mg
18 Years - Latin American Cooperative Oncology Group
Palbociclib Combined With an Aromatase Inhibitor in Breast CancerNCT04047758
Breast Cancer
Palbociclib + L...
Letrozole
18 Years - 70 YearsShengjing Hospital
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02785939
CCND1 Gene Ampl...
CCND2 Gene Ampl...
CCND3 Gene Ampl...
CDK4 Gene Ampli...
Recurrent Squam...
Stage IV Squamo...
Docetaxel
Laboratory Biom...
Palbociclib
18 Years - SWOG Cancer Research Network
Palbociclib Combined With an Aromatase Inhibitor in Breast CancerNCT04047758
Breast Cancer
Palbociclib + L...
Letrozole
18 Years - 70 YearsShengjing Hospital
Pilot Trial for Treatment of Recurrent GlioblastomaNCT05432518
Glioblastoma
Recurrent Disea...
Recurrent Gliob...
Afatinib
Dasatinib
Palbociclib
Everolimus
Olaparib
18 Years - AHS Cancer Control Alberta
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377
Advanced Malign...
Anatomic Stage ...
Anatomic Stage ...
Locally Advance...
Malignant Femal...
Metastatic HER2...
Metastatic Mali...
Recurrent Endom...
Recurrent Fallo...
Recurrent Malig...
Recurrent Malig...
Recurrent Ovari...
Recurrent Prima...
Unresectable HE...
Unresectable Ma...
Alpelisib
Binimetinib
Biopsy
Biospecimen Col...
Bone Marrow Asp...
Bone Scan
Computed Tomogr...
Echocardiograph...
Fluorouracil
Fulvestrant
Ipatasertib
Leucovorin
Magnetic Resona...
Multigated Acqu...
Mutation Carrie...
Neratinib Malea...
Nilotinib Hydro...
Olaparib
Oxaliplatin
Paclitaxel
Palbociclib
Panitumumab
Positron Emissi...
Selumetinib Sul...
Sotorasib
- National Cancer Institute (NCI)
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerNCT02664935
Non-Small Cell ...
Carcinoma, Squa...
Adenocarcinoma
AZD4547
Vistusertib
Palbociclib
Crizotinib
Selumetinib
Docetaxel
AZD5363
Osimertinib
Durvalumab
Sitravatinib
AZD6738
18 Years - University of Birmingham
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)NCT04436744
Early Breast Ca...
Giredestrant
Anastrozole
Palbociclib
Surgery
18 Years - Hoffmann-La Roche
HR+/HER2- Advanced Breast Cancer and Endocrine ResistanceNCT03322215
Breast Cancer M...
Palbociclib
Fulvestrant
Capecitabine
18 Years - Karolinska University Hospital
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast CancerNCT03774472
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Hydroxychloroqu...
Letrozole
Palbociclib
18 Years - M.D. Anderson Cancer Center
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid TumorsNCT03454035
Tumor, Solid
Pancreatic Canc...
Melanoma
Ulixertinib
Palbociclib
18 Years - 99 YearsUNC Lineberger Comprehensive Cancer Center
Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast CancerNCT03284957
Breast Cancer
Amcenestrant
Palbociclib
Alpelisib
Everolimus
Abemaciclib
18 Years - Sanofi
Study of Palbociclib in MLL-rearranged Acute LeukemiasNCT02310243
Acute Myeloid L...
Acute Lymphobla...
Palbociclib
18 Years - University of Ulm
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)NCT06126276
Malignant Femal...
Malignant Solid...
Recurrent Malig...
Recurrent Malig...
Biopsy
Biospecimen Col...
Computed Tomogr...
Echocardiograph...
Magnetic Resona...
Multigated Acqu...
Neratinib Malea...
Palbociclib
18 Years - National Cancer Institute (NCI)
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment TrialNCT05554367
Malignant Solid...
Ovarian Low Gra...
Pancreatic Carc...
Stage IV Ovaria...
Stage IV Pancre...
Binimetinib
Biopsy
Biospecimen Col...
Bone Scan
Computed Tomogr...
Magnetic Resona...
Palbociclib
18 Years - National Cancer Institute (NCI)
Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in JapanNCT05399329
Breast Cancer
Palbociclib
Endocrine thera...
20 Years - Pfizer
Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant ChemotherapyNCT04137640
Breast Cancer
palbociclib com...
epirubicin comb...
18 Years - 70 YearsShengjing Hospital
Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATENCT04720768
Melanoma
Metastasis
Binimetinib
Encorafenib
Palbociclib
18 Years - 100 YearsPeter MacCallum Cancer Centre, Australia
Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal CancerNCT03981614
Metastatic Colo...
Stage IV Colore...
Stage IVA Color...
Stage IVB Color...
Stage IVC Color...
Unresectable Ca...
Binimetinib
Palbociclib
Trifluridine an...
18 Years - Academic and Community Cancer Research United
Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese PatientsNCT04858997
Breast Neoplasm...
Palbociclib
AI
18 Years - Zhejiang Cancer Hospital
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast CancerNCT04567420
Breast Cancer
Palbociclib
Fulvestrant
Adjuvant Therap...
- Criterium, Inc.
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast CancerNCT04288089
Receptors, Estr...
Genes, Erbb-2
Breast Neoplasm...
Palbociclib (75...
H3B-6545 (150, ...
18 Years - Eisai Inc.
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast CancerNCT04872608
Metastatic Brea...
Unresectable Br...
Letrozole
Palbociclib
Onapristone ER
18 Years - Memorial Sloan Kettering Cancer Center
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: